- Stable sales in a persistently difficult European economy
- 2013 objective of 3-5% organic sales growth maintained
- Solid commercial negotiations underway
- Confirmed favorable growth prospects in emerging markets and in industrial applications
MARCY L'ETOILE, France - April 23, 2013 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2013.
Consolidated sales stood at €359 million for the period, unchanged from first-quarter 2012 at constant exchange rates and scope of consolidation.
Download
- Filename
- biomerieux_-_pr_sales_q1_2013.pdf
- Size
- 280 KB
- Format
- application/pdf